Immune Related Adverse Events of Checkpoint Inhibitors
ACR on Air
00:00
Treatment Approaches for Immune-Related Adverse Events
Exploring the use of corticosteroids as the primary therapy for immune-related adverse events from checkpoint inhibitors, the chapter discusses challenges in dosing and progression to disease-modifying drugs. It delves into the considerations of immunosuppression timing for anti-tumor responses and the impact of TNF inhibitors on cancer outcomes. Ongoing studies on IL-6 blockade benefits, heterogeneous inflammatory arthritis, and PD-1 drug use in rheumatoid arthritis treatment are also discussed.
Transcript
Play full episode
